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Abstract The structure of the complex of Ras with the Ras-
binding domain of its effector RalGDS (RGS-RBD), the first
genuine Ras-effector complex, has been solved by X-ray
crystallography. As with the Rap-RafRBD complex (Nasser et
al., 1995), the interaction is via an inter-protein L-sheet between
the switch I region of Ras and the second strand of the RGS-
RBD sheet, but the details of the interactions in the interface are
remarkably different. Mutational studies were performed to
investigate the contribution of selected interface residues to the
binding affinity. Gel filtration experiments show that the
RasWRGS-RBD complex is a monomer. The results are compared
to a recently determined structure of a similar complex using a
Ras mutant (Huang et al., 1998) and are discussed in relation to
partial loss-of-function mutations and the specificity of Ras
versus Rap binding.
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1. Introduction
Ras is a major regulator of cell growth and development,
and oncogenic mutants of Ras induce transformation of cells.
It is a signal switch molecule that cycles between the GDP-
bound inactive and the GTP-bound active form. In the active
form Ras interacts with e¡ector molecules which are de¢ned
as binding tightly to the GTP-bound form. Several e¡ectors
have been identi¢ed each of which is believed to initiate a
cascade of signal transduction reactions, the combination of
which is needed for biological activity of Ras [3]. In order to
dissect these pathways and de¢ne the requirements for each of
them, partial loss-of-function mutations have been de¢ned
which bind selectively to only a subset of e¡ector molecules
[4,5] and have been used to analyze Ras function [6^12].
The major downstream target of Ras is the protein kinase
Raf, which activates the MAP kinase (Erk) cascade [13^16].
The structure of the Ras-binding domain (RBD) of c-Raf-1
alone [17] or in complex with a Ras homologue Rap or Raps
( = Rap(E30D K31E)), have shown that RafRBD binds to
Rap(s) by forming an apparent inter-protein L-sheet involving
the e¡ector (switch I) region of Ras [1,18]. Another e¡ector of
Ras is RalGDS (for Ral guanine nucleotide dissociation stim-
ulator) [19^21], and its isoforms Rgl, Rlf and Rgl-2 [22^24],
all of which have an RBD at the C-terminal end. The struc-
ture of the RBD of RalGDS (RGS-RBD from now on)
bound to a Ras mutant (E31K) has recently been determined
[2]. Here we have solved the structure of Ras itself bound to
the RBD of RalGDS and determined the biochemical proper-
ties of Ras-RalGDS complexes. The results are discussed in
light of the earlier structure [2], the stoichiometry of the com-
plex, partial loss-of-function mutations and signaling proper-
ties of Ras and Rap complexes.
2. Materials and methods
2.1. Biochemistry
Mutants of Ras and RGS-RBD, respectively, were generated by
standard PCR mutagenesis protocols. The preparation of proteins
and the nucleotide exchange procedure is as described [25]. The com-
plex between RasWGppNHp and RGS-RBD was puri¢ed by size ex-
clusion chromatography. For crystallization C-terminally truncated
Ras (residues 1^166) was used and full length Ras for biochemical
studies. The KD values for wild-type and mutant proteins were ob-
tained by the GDI method which is based on the observation that the
guanine nucleotide dissociation is inhibited (GDI) by RGS-RBD
binding as described [25]. For determination of the molecular mass,
gel ¢ltration of the RasWRGS-RBD complex was eluted from a Phar-
macia Superdex 75 column (10/30 cm), in 50 mM Tris pH 7.4, 5 mM
MgCl2, 2 mM DTE.
2.2. Crystallization and structure determination
The RasWRGS-RBD complex was crystallized at room temperature
from 1.3 M ammonium sulfate, either without additives or with 200
mM MES pH 6.0^6.5 and 100 mM MgCl2. The former solution
yielded orthorhombic crystals with space group C2221, a = 53.4 Aî ,
b = 96.0 Aî , c = 105.9 Aî . The crystals showed a high mosaicity of
2.2‡. The latter crystallization solution produced hexagonal P6322
crystals with a = b = 94.3 Aî , c = 164.8 Aî and a mosaicity of 0.6‡.
The crystals di¡racted to 3.4 Aî at maximum even at a strong synchro-
tron beamline. Both crystal forms have one molecule of the complex
per asymmetric unit.
Di¡raction data were collected on a multi-wire area detector (Nico-
let/Xentronics, Madison, WI, USA) using a rotating anode X-ray
generator and data sets were processed using the XDS software suite
[26]. Both crystal forms were solved by molecular replacement using
AMORE [27] and RGS-RBD [28] and Ras-GTP as model. The omit-
ted nucleotide showed up in the di¡erence density indicating the cor-
rect solution. However, the density of the missing RGS-RBD moiety
did not show up in su⁄cient quality using one or the other data set by
itself. Molecular replacement with the known NMR- and X-ray struc-
tures of uncomplexed RGS-RBD [28,29] was unsuccessful. Therefore,
multi-crystal averaging was performed in combination with solvent
£attening procedures with the program DMMULTI [27]. The result-
ing electron density map allowed tracing of the missing RGS-RBD
backbone (except residues 50^55 and 78^89) and the localization of
prominent side chains. Since the maximum resolution of both data
sets is only 3.4 Aî , the known structures of RGS-RBD had to be used
as templates, i.e. stretches of secondary structure elements were
moved into the averaged density. Modeling was performed using
the program ‘O’ [30]. All attempts to re¢ne the model failed to im-
prove the free R factor signi¢cantly, which is 35.4% for the ¢nal
model. However, the quality of the averaged density allowed the un-
ambiguous positioning of the RGS-RBD moiety and the analysis of
the interactions in the interface. The correctness of the model was
indicated by the fact that the modeled RGS-RBD moiety yielded
the correct solution in a rotation function search whereas the
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Fig. 1. Structure of the complex. a, b show the di¡erent crystal packing of the main chain model in the two space groups with the disul¢de
bridges between symmetry related molecules highlighted as green, dashed lines (a for space group C2221, b for P6322). c, d show ribbon dia-
grams of the RasWRGS-RBD (c) and the RapWRafRBD (d) complex. The ¢gure was produced with MOLSCRIPT [33].
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NMR- or X-ray model of the RGS-RBD alone did not. The crystallo-
graphic data are summarized in Table 1.
3. Results and discussion
3.1. Complex structure
From deletion cloning the Ras-binding domain (RBD) of
human RalGDS, RGS-RBD, was de¢ned as a fragment of 97
C-terminal residues (corresponding to residues 790^886, [31]).
The structure of RGS-RBD has been solved by heteronuclear
NMR spectroscopy as well as X-ray crystallography and was
shown to have the same ubiquitin superfold as the Ras-bind-
ing domain of the protein kinase c-Raf-1, RafRBD [28,29].
The structure of the RasWRGS-RBD complex was deter-
mined in spite of the relatively poor data quality by multi-
crystal averaging using two di¡erent crystal forms as de-
scribed in Section 2. No density was visible for residues 50
to 55 and residues 78 to 89 which could be due to either
inherent £exibility or to di¡erent conformations in the two
crystal forms. Region 50^55 shows only few structural con-
straints in the NMR structure which would support the no-
tion that it might be inherently £exible. In the crystal, RGS-
RBD is connected to a symmetry related RBD molecule via
disul¢de bridges in both crystal forms, although the packing
of the molecules is di¡erent in each (Fig. 1a, b). Since the
crystals took a long time to grow (ca. 6 months), the forma-
tion of the correct disul¢de bridges might have been the limit-
ing factor for crystallization. The relative orientation of Ras
and RGS-RBD is the same in the two crystal forms in spite of
the di¡erent crystal contacts and packing, indicating that the
complex structure is not disturbed by the disul¢de bridges.
The overall structure of the complex is shown in Fig. 1c as
a ribbon plot. Contrary to the results of Huang et al. [2], one
Ras molecule interacts with only one RGS-RBD molecule in
both of our crystal forms. Therefore we believe dimerization
to be caused by crystal packing, consistent with biochemical
studies (see below).
The major feature of the interaction is the alignment of the
two proteins along the outer strands of their L-sheets such
that an apparent continuous L-sheet between the two proteins
is formed, similar to what was found for the wild-type RapW
RafRBD complex [1], and for the mutant RapsWRafRBD
complex believed to be a good mimic of the RasWRafRBD
complex [18] (Fig. 1c, d), and has also been shown for the
mutant RasWRGS-RBD complex [2]. The dissociation of nu-
cleotide is inhibited by the binding of the RalGDS e¡ector
[25] but as in the RafRBD complex, this e¡ect is indirect as
the nucleotide-binding site is not directly involved in or situ-
ated at the interface of the complex [1,18]. The structure of
RGS-RBD is not changed appreciably as the superposition of
free RGS-RBD from both the NMR and X-ray determination
[28,29] together with complexed protein shows no large devi-
ation and has an rms di¡erence of 2.4 and 1.8 Aî for 60 CK
atoms, respectively (not shown).
As mentioned above, RGS-RBD and RafRBD share the
same fold and overlay quite well with an rms di¡erence of
3.6 Aî for 49 CK atoms (Fig. 2a). However, if Ras and Rap
from the complexes are superimposed, the corresponding
RBDs are rotated by approximately 35‡ when viewed from
the direction of the Ras or Rap moiety (Fig. 2b). In the RapW
RafRBD complex, the L-sheet of the RBD nicely continues
the L-sheet of Ras, whereas in the RasWRGS-RBD the two
adjacent L-strands of Ras and RGS-RBD are tilted due to
the 35‡ rotation. However, the number of possible main chain
interactions which are typical for a L-sheet is about the same
in the two complexes and quite small since the majority of the
interactions is formed by side chains.
3.2. Structural and biochemical analysis of the interface
As seen with higher resolution for the Ras mutant [2], the
interaction between Ras and RGS-RBD is between the ¢rst
two L-strands and the long helix K1 of the RBD using the
mostly hydrophilic side chains of Arg-16, Lys-28, Ser-29 and
Lys-48 of RGS-RBD, similar to the interaction between
RafRBD and Rap and the Ras homologue Raps [1,18] as
shown schematically in Fig. 3. Similar hydrophilic residues
of RGS-RBD and RafRBD are involved in the binding of
Ras, although it is obvious that RGS-RBD has less positively
Fig. 2. Overlay of the RafRBD (pink) and RGS-RBD (blue) backbones. In a, the molecules were ¢tted by a least squares ¢t procedure using
the program ‘O’ [30]; in b, the Ras and the Rap moieties of the corresponding complexes were ¢tted on top of each other to show the ‘rota-
tion’ (arrow) of the RBDs. The ¢gure was drawn using GRASP [34].
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charged residues in the interface. On the Ras side residues
Asp-33, Pro-34, Ile-36, Glu-37, Asp-38, Ser-39 and Tyr-40
from the switch I region are involved in the interaction.
Both e¡ectors Raf and RalGDS share common binding part-
ners on Ras, di¡erences are seen for residues Glu-31, Ser-39
and Arg-41 which interact with RafRBD but not with RGS-
RBD (Fig. 3), whereas Pro-34 and Tyr-40 interact with RGS-
RBD but not with RafRBD.
To relate the structural ¢ndings with a more quantitative
analysis of the interaction and to determine the importance of
individual amino acids, the a⁄nity of the RasWRGS-RBD
complex in solution was investigated with appropriate mu-
tants of RGS-RBD and Ras. The basic residues Arg-16,
Lys-28 and Lys-48 on RGS contribute strongly to the inter-
action, whereas other residues close to the interface such as
Asn-23, Asn-25 or Tyr-27 have a weaker e¡ect (Table 2).
RGS-RBD contains a stretch of four consecutive glutamic
acid residues between K1 and L3, the charge but not the se-
quence of which is conserved in RalGDSs. They have been
found to be involved in binding to a Ras (E31K) mutant in
the crystal structure of its complex with RGS-RBD [2]. Mu-
tants E52A and E53A show a slightly stronger binding to
wild-type Ras, as if these residues had an inhibitory e¡ect
on the interaction.
Glu-37 forms only a weak ionic interaction with Arg-16 of
RalGDS. Correspondingly the a⁄nity of Ras(E37G) is re-
duced only 1.6-fold (Table 2), in line with the assumption
from transfection experiments that this mutant is still inducing
the RalGDS pathway, whereas Glu-37 is crucial for the Raf
pathway [6^12]. From residues mutated in Ras, Thr-35, Asp-
38 and Tyr-40 have apparently the strongest e¡ect on binding
energy. D38A is a very drastic mutation which seems to e¡ect
all Ras pathways, whereas the somewhat weaker D38E allele
is still able to interact with Raf kinase [7]. Asp-38 is the most
important contact residue in the RGS-RBD complex and is
located close to the residues Lys-28 and Lys-48. The D38E
mutation might disturb the network of charges around resi-
dues Asp-33, Asp-38 of Ras and Lys-28, Lys-48 of RGS-
RBD, but not in the RafRBD interface with Lys-28 replaced
by Thr-68, explaining its selective biological action. Tyr-40
forms a considerable part of the contact surface, forming
numerous hydrophobic and hydrophilic contacts which would
explain the loss of a⁄nity of the Y40C mutant.
Table 1
Data collection
Crystal 1 Crystal 2
Space group C2221 P6322
Unit cell a = 53.4 Aî a = b = 94.3 Aî
b = 96.0 Aî c = 164.8 Aî
c = 105.9 Aî
Resolution 45^3.4 Aî 35^3.4 Aî
Unique re£ections 8824 4528
Observed re£ections 89647 14741
Completeness 99.3% 90.2%
Completeness 3.5^3.4 Aî 98.0% 72.1%
GI/cf 16.3 20.1
GI/cf3.5^3.4 Aî 2.3 7.9
Rasym 16.0% 9.1%
Rasym 3.5^3.4 Aî 67.4% 14.0%
Rcrysb 30.9%
Rfree 35.4%
Molecular replacementc : R factor 42.3%/50.6% 40.7%/51.6%
Molecular replacementc : correlation 44.0/14.6 51.8/15.0
aRsym =4hkl4i dIi-GIfd/4hkl4i Ii , where Ii is the intensity for the ith measurement of an equivalent re£ection with indices h, k, l.
bRcrys =4hkleFobsd3dFcalce/4hkl dFobsd, where Fobs denotes the observed structure factor amplitude and Fcalc denotes the structure factor amplitude
calculated from the model. 10% of re£ections were used to calculate Rfree.
cFor both molecular replacements, RasWGTP was used as model (PDB code 5p21). The values after the slash are the R factors and correlations
of the second highest peak.
Fig. 3. Schematic comparison of the interactions of Ras with RGS-
RBD as compared to those of Raps (Rap mutant with D30E,
E31K) with RafRBD [1,18].
FEBS 22016 18-5-99 Cyaan Magenta Geel Zwart
I.R. Vetter et al./FEBS Letters 451 (1999) 175^180178
It had been anticipated that Thr-35 would be involved in
the interface since the mutation T35S reduces the a⁄nity to
RGS-RBD at least 30-fold (Table 2). Surprisingly the struc-
ture of the RasWRGS-RBD complex shows no direct involve-
ment of Thr-35 in complex formation. In the structure of the
Ras(E31K)WRGS-RBD complex described by Huang et al. [2]
an indirect interaction between the hydroxyl side chain of
Thr-35 and Lys-52 via a water molecule was shown. However
such an interaction should also be possible with a Ser-35 side
chain. The reduced a⁄nity for RGS-RBD is thus not obvious
from the X-ray structures.
3.3. Ras versus Rap signaling
Both Ras and Rap bind to the same set of e¡ectors in vitro
which is not surprising considering the similar e¡ector regions,
although in vivo Rap appears to have a di¡erent biological
function [32]. RafRBD binds Ras about 100-fold tighter than
Rap [25], and the di¡erence is due to an unfavorable interac-
tion between Lys-84 of RafRBD and Lys-31 of Rap, which is
Glu in Ras [1,18]. The opposite relative a⁄nity is found for
RGS-RBD, with high a⁄nity to Rap and about 100-fold low-
er for Ras, with the mutation of Glu-31 in Ras to lysine
increasing the a⁄nity (Table 2; [25]). In the structure of the
complex of RGS-RBD with the E31K mutant of Ras [2], Lys-
31 was found to interact with the side chains of Asp-51, Asn-
54 and Asp-56 (corresponding to Asp-47, Asn-50 and Glu-52
in human RalGDS used here). In the wild-type RasWRGS-
RBD complex this highly charged loop appears disordered
and does not show a direct interaction. A possible explanation
might be the long-range charge-charge interactions across the
interface. The strong negative potential caused by the highly
negatively charged loop 52^58 (L3) of RGS-RBD, as seen
from the isopotential contours of the RGS-RBD moiety in
the RasWRGS-RBD complex appears to interfere with Glu-
31 (not shown). In support of this, the less negatively charged
mutants E52A, E53A and E52K of RGS-RBD show a slightly
higher a⁄nity to Ras (Table 2). The increase in a⁄nity to
RalGDS due to charge reversal at position 31 is highlighted
by the X-ray structure of the Ras(E31K) complex, where Lys-
31 makes contact to three Asp/Asn residues of the K1-L3
region [2].
3.4. Involvement of switch II and stoichiometry of the
RasWRGS-RBD complex
In the structure presented here, switch II region of Ras is
not involved in the interaction. Glu-63 in switch II was found
to be involved in a number of contacts with a second molecule
of RGS-RBD in the crystal of the Ras(E31K)WRGS-RBD
complex [2]. However, Glu-63 can be mutated to Ala without
any e¡ect on a⁄nity, strengthening the assumption that the
interaction of RGS-RBD with switch II found in the Ras-
(E31K) mutant structure is not relevant for complex forma-
tion in solution. To further address the question if the com-
plex of Ras and RGS-RBD forms a dimer in solution, size
exclusion chromatography was applied to the proteins. This
technique is based on the linear relationship between the log-
arithm of the molecular weight (MW) of the proteins and
their elution volume. Fig. 4 shows the elution volume for
the RasWRGS-RBD complex, which is found at a position
which corresponds to the monomer form. For comparison
the calculated elution volume for the dimer complex is indi-
cated by an arrow. This ¢nding supports our notion that the
dimer formation via the switch II region observed in the Ras-
(E31K) mutant structure [2] is due to packing in the crystal
and that the interaction between Ras and RGS-RBD does
only involve the switch I region of Ras.
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